SCHEMBL2210302

SCHEMBL2210302

Cn1cc(-c2ccc3nccc(Oc4ccc(Nc5nnc(-c6ccccc6)c6ccccc56)cc4)c3c2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.51
CDK8 P49336 1/20 0.51
FGFR2 P21802 2/20 0.48
ALK Q9UM73 1/20 0.48
EGFR P00533 3/20 0.47
ERBB2 P04626 3/20 0.47
ERBB4 Q15303 3/20 0.47
AURKA O14965 3/20 0.45
AURKB Q96GD4 2/20 0.45
TPX2 Q9ULW0 2/20 0.45
MAPT P10636 3/20 0.43
LMNA P02545 1/20 0.43
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
RAB9A P51151 1/20 0.42
RET P07949 2/20 0.41
RIPK2 O43353 1/20 0.41
RIPK3 Q9Y572 1/20 0.41
AXL P30530 1/20 0.41
ENPP3 O14638 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2211767 0.83 FGFR2 (0.58) FGFR2EGFRAURKAAURKBTPX2
SCHEMBL2209074 0.81 FGFR2 (0.50) FGFR2ERBB2AURKAAURKBTPX2
SCHEMBL15663737 0.81 MAPT (0.45) CCNCCDK8FGFR2MAPTLMNA
SCHEMBL2204540 0.80 MAPT (0.55) FGFR2EGFRAURKAAURKBTPX2
SCHEMBL2207029 0.80 FGFR2 (0.72) FGFR2EGFRMAPTLMNARIPK2
SCHEMBL2211183 0.79 FGFR2 (0.48) FGFR2AURKAAURKBTPX2MAPT
SCHEMBL2209315 0.78 MAPT (0.54) FGFR2MAPTLMNAALDH1A1ENPP3
SCHEMBL2210999 0.78 CCNC (0.49) CCNCCDK8FGFR2AURKAAURKB
SCHEMBL2210992 0.78 FGFR2 (0.58) FGFR2EGFRAURKAAURKBTPX2
SCHEMBL2208900 0.77 FGFR2 (0.63) FGFR2AURKAAURKBTPX2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981891-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2011-07-19 US claimed
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2010-11-04 US claimed
US-20140336182-A1 Aurora Kinase Modulators and Method of Use AMGEN INC (US) 2014-11-13 US disclosed
US-20140336182-A1 Aurora Kinase Modulators and Method of Use AMGEN INC (US) 2014-11-13 US disclosed
US-20140336182-A1 Aurora Kinase Modulators and Method of Use AMGEN INC (US) 2014-11-13 US disclosed
EP-2137177-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-05-07 EP disclosed
EP-2137177-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-05-07 EP disclosed
US-8557816-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2013-10-15 US disclosed
US-8557816-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2013-10-15 US disclosed
US-8557816-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2013-10-15 US disclosed
US-20120122847-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2012-05-17 US disclosed
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2010-11-04 US disclosed
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2010-11-04 US disclosed
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2010-11-04 US disclosed
US-7776857-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2010-08-17 US disclosed
US-7776857-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2010-08-17 US disclosed
US-7776857-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2010-08-17 US disclosed
US-20090069297-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-03-12 US disclosed
US-20090069297-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-03-12 US disclosed
US-20090069297-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336182-A1 Aurora Kinase Modulators and Method of Use AURKC, AURKA, CDK1 CCNC 32/4885CDK8 6/4885FGFR2 334/4885
US-20090069297-A1 Aurora kinase modulators and method of use AURKC, AURKA, CDK1 CCNC 32/4885CDK8 6/4885FGFR2 334/4885
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 CCNC 32/4885CDK8 6/4885FGFR2 334/4885
US-20120122847-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 CCNC 32/4885CDK8 6/4885FGFR2 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.